TNF Inhibitors Should Carry Class Warnings For Lymphoma, CHF – FDA Cmte.
Executive Summary
Tumor necrosis factor inhibitor labeling should carry class warnings for the risks of lymphoma and congestive heart failure, FDA's Arthritis Advisory Committee recommended March 4